Drug Profile

QL 301

Alternative Names: QL-301

Latest Information Update: 04 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator QLSF Biotherapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cancer

Most Recent Events

08 Apr 2022 Phase-I clinical trials in Cancer in USA (Intraperitoneal)
08 Apr 2022 Pharmacodynamics and adverse events data from preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research
12 Aug 2020 QLSF Biotherapeutics announces intention to submit IND application with the US FDA by Q2 2021 (QLSF Biotherapeutics pipeline, August 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com